Target intelligence / Profile preview

Meteorin-like protein (METRNL) (METRNL)

Target
METRNL
Molecular classification
Secreted protein, Neurotrophic factor, Cytokine-like protein
01

Overview

Meteorin-like protein (METRNL), frequently referred to as Cometin in neurobiological contexts, is a secreted protein that functions as a neurotrophic factor with activity similar to Nerve Growth Factor (NGF) (Jørgensen et al., 2012, PMID: 22351612). It is highly expressed in the supporting cells of the sensory epithelia and plays a vital role in the survival and neurite outgrowth of sensory neurons, such as those in the spiral ganglion of the inner ear (UniProt Q6EBC1). METRNL exerts its effects by activating downstream signaling pathways, including the JAK/STAT3 and MAPK/ERK cascades, which mediate its neuroprotective and regenerative properties. Beyond the nervous system, METRNL (also known as Subfatin) is involved in metabolic regulation, promoting thermogenesis in adipose tissue and exerting anti-inflammatory effects (Rao et al., 2014, PMID: 25470031). Due to its multi-faceted roles, it is considered a potential therapeutic target for treating sensorineural hearing loss, peripheral neuropathy, and metabolic diseases like type 2 diabetes. Its ability to support both neurons and their supporting cells makes it a versatile candidate for regenerative medicine.

Other names
CometinSubfatinMeteorin-betaMETRNLMeteorin-like protein
02

Mechanism of action

METRNL acts as a secreted neurotrophic factor that binds to its receptor complex to activate the JAK/STAT3 and MAPK/ERK signaling pathways, which promote neuronal survival and neurite outgrowth (Jørgensen et al., 2012, PMID: 22351612).

03

Biological functions

Signal transductionCell survivalNeurite outgrowthNeuroprotectionThermogenesisAnti-inflammatory response
04

Disease associations

Sensorineural hearing lossPeripheral neuropathyNeurodegenerative diseaseObesityType 2 diabetesInflammation
05

Safety considerations

Potential for systemic metabolic side effectsRisk of oncogenic signaling activation (STAT3/MAPK)Immunogenicity of recombinant proteinsLack of long-term clinical safety data
06

Interacting drugs

Recombinant Meteorin-like protein (experimental)
07

Biomarkers

METRNL serum levelsPhospho-STAT3 (p-STAT3)Phospho-ERK1/2 (p-ERK1/2)

Beyond the preview

Go deeper on Meteorin-like protein (METRNL) (METRNL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meteorin-like protein (METRNL) (METRNL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call